In NSCLC, Li et al. [20] discovered complementary binding sites between UCA1 and miRNA-495, and indicated that UCA1 promoted cisplatin resistance of NSCLC by regulating the miRNA-495/Nuclear factor-erythroid 2-related factor 2 (NRF2) axis as ceRNA. The gene discussed is UCA1; the disease is non-small cell lung carcinoma.